JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin

  • 0Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
In Vivo +

|

April 28, 2025

|

April 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Cancer-induced pain (CIP) in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV) is linked to worse survival. Early pain management may improve outcomes for UC patients receiving EV therapy.

Area Of Science

  • Oncology
  • Pain Management
  • Urothelial Carcinoma Research

Background

  • Cancer-induced pain (CIP) significantly impacts patient quality of life.
  • The prognostic role of CIP in urothelial carcinoma (UC) patients receiving enfortumab vedotin (EV) remains unclear.

Purpose Of The Study

  • To retrospectively investigate the prognostic significance of CIP in UC patients treated with EV.
  • To determine if pre-treatment CIP is associated with survival outcomes in this patient cohort.

Main Methods

  • Retrospective analysis of clinical data from 114 locally advanced or metastatic UC patients treated with EV.
  • Assessment of factors including age, metastasis site, ECOG Performance Status (PS), and pre-treatment CIP status.
  • CIP determination based on clinical records of cancer-related pain or analgesic use.

Main Results

  • Patients with CIP had a higher incidence of bone metastasis.
  • No significant difference in progression-free survival was observed between patients with and without CIP.
  • CIP was a significant predictor of poorer overall survival (OS), alongside liver metastasis and ECOG PS.

Conclusions

  • Pre-treatment CIP is a significant predictor of reduced OS in UC patients receiving EV.
  • Early management of CIP or initiating EV therapy before CIP development may enhance survival outcomes.

Keywords:

Related Concept Videos

Cancer Survival Analysis 01:21

308

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies 02:57

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine 02:50

4.8K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...